| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| Targets |
Human Endogenous Metabolite Microbial Metabolite
|
|---|---|
| ln Vitro |
Vanillylmandelic acid has antioxidant action; the IC50 value is calculated using the UV-Vis decolorization DPPH experiment, where the quantity of VMA needed to eliminate 50% of the initial concentration of free radical is 33*10-6 M[1].
|
| ln Vivo |
A significant difference is observed between the groups who received vanillylmandelic acid (intra-arterial injection during a 1-minute interval; 1, 10, and 100 mg/kg; the 60-minute observation period) and the control group. After 1, 10, and 100 mg/kg, vanillylmandelic acid reduces heart rate by 17.5%, 17.9%, and 18.9%, respectively. When wistar rats are given 1, 10, and 100 mg/kg, respectively, their mean blood pressure decreases by 13.5% in control animals and by 37%, 23%, and 26% in wistar rats[1].
|
| References |
|
| Additional Infomation |
Vanillylmandelic acid is an aromatic ether that is the 3-O-methyl ether of 3,4-dihydroxymandelic acid. It has a role as a human metabolite. It is an aromatic ether, a 2-hydroxy monocarboxylic acid and a member of phenols. It is functionally related to a mandelic acid. It is a conjugate acid of a vanillylmandelate.
Vanillylmandelic acid is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). Vanillylmandelic acid has been reported in Homo sapiens, Pogostemon cablin, and Phaseolus vulgaris with data available. Vanillylmandelic Acid is an aromatic ether that is a product of catecholamine metabolism. Vanillylmandelic acid may be a used as marker for tumors that secrete catecholamines, such as neuroblastoma or pheochromocytoma. A 3-O-methyl ether of 3,4-dihydroxymandelic acid. It is an end-stage metabolite of CATECHOLAMINES; EPINEPHRINE; and NOREPINEPHRINE. |
| Molecular Formula |
C9H10O5
|
|---|---|
| Molecular Weight |
198.17
|
| Exact Mass |
198.052
|
| CAS # |
55-10-7
|
| Related CAS # |
Vanillylmandelic acid-d3;74495-70-8;Vanillylmandelic acid-d;53587-34-1
|
| PubChem CID |
1245
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
421.3±45.0 °C at 760 mmHg
|
| Melting Point |
132-134 °C (dec.)(lit.)
|
| Flash Point |
173.7±22.2 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
-0.11
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
205
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CGQCWMIAEPEHNQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H10O5/c1-14-7-4-5(2-3-6(7)10)8(11)9(12)13/h2-4,8,10-11H,1H3,(H,12,13)
|
| Chemical Name |
2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (1261.54 mM)
H2O: 100 mg/mL (504.62 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (126.15 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0462 mL | 25.2309 mL | 50.4617 mL | |
| 5 mM | 1.0092 mL | 5.0462 mL | 10.0923 mL | |
| 10 mM | 0.5046 mL | 2.5231 mL | 5.0462 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
